ANKMY2 Inhibitors
ANKMY2 inhibitors refer to a specialized class of chemical compounds that selectively target and impede the activity of the ANKMY2 protein, which is encoded by the ANKMY2 gene. ANKMY2, a protein associated with cytoskeletal organization and vesicle transport, plays a crucial role in intracellular trafficking and cellular signaling pathways. The inhibitors of ANKMY2, therefore, have a specific action mechanism: by binding to the active or allosteric sites of the ANKMY2 protein, they disrupt its normal function, leading to a decrease in the protein's activity. This disruption can affect various biological processes that rely on the proper distribution and movement of vesicles and organelles within the cell. The inhibitors may work by altering the protein's structural conformation, obstructing the substrate-binding sites, or interfering with the regulatory components that modulate ANKMY2's activity.
The chemical compounds classified as ANKMY2 inhibitors are structurally diverse but united by their ability to influence the cellular activities governed by ANKMY2. These inhibitors can be designed to interact with the protein in several ways, such as by mimicking the natural substrates of ANKMY2, competing with ATP binding, or destabilizing the protein's interaction with its partners, which is essential for its function. The consequences of such inhibition are multifold, affecting the dynamic organization of the cytoskeleton, which is vital for processes like cell division, migration, and intracellular transport. By impeding the regulatory role of ANKMY2 in these cellular activities, the inhibitors effectively modulate the intracellular traffic and the signaling cascades that depend on spatially and temporally coordinated vesicle movement. The specificity of ANKMY2 inhibitors provides valuable insights into the intricate network of cellular regulation, as well as their potential utility in research settings to dissect the molecular pathways involving ANKMY2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that can indirectly lead to reduced ANKMY2 function by impeding the PI3K/AKT signaling pathway, which is crucial for many cellular processes including protein trafficking. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor that, like Wortmannin, suppresses the PI3K/AKT pathway, potentially resulting in decreased ANKMY2 activity due to the role of this pathway in vesicle formation and trafficking where ANKMY2 is involved. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
A selective inhibitor of Cdc42, a small GTPase. Cdc42 is involved in the regulation of cytoskeleton organization. By inhibiting Cdc42, ML141 could indirectly decrease ANKMY2 activity by affecting vesicle movement and protein sorting. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
A Rac1 inhibitor that disrupts Rac1-mediated signaling involved in actin polymerization and membrane ruffling. ANKMY2, being associated with vesicle trafficking, may have reduced activity when Rac1-dependent cellular processes are inhibited. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor, which prevents the activation of the MAPK/ERK pathway. This pathway is involved in various cellular functions including endocytosis and vesicular trafficking, potentially influencing ANKMY2's role in these processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that may indirectly inhibit ANKMY2 by modulating the cellular stress response, thereby potentially affecting the protein sorting mechanisms that ANKMY2 is part of. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which could downregulate cellular processes such as vesicular transport and protein sorting, thus possibly reducing ANKMY2 activity indirectly. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
A protein kinase C (PKC) inhibitor which may affect ANKMY2 by altering vesicle formation and trafficking pathways, as PKC is involved in the phosphorylation of proteins related to these processes. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
An agent that disrupts Golgi apparatus structure and function, which would likely decrease ANKMY2 activity because ANKMY2 is involved in the vesicular transport from the Golgi. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A GTPase inhibitor that targets dynamin, involved in clathrin-mediated endocytosis, and could thus reduce ANKMY2 function if ANKMY2 is involved in this kind of vesicular trafficking. | ||||||